Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
The recent merger of Patheon and DPP makes the company one of the largest outsourcing players in the market. CEO Jim Mullen explains why the company now has to live up to the hype.